Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. The unique structure of CAR endows T cell tumor specific cytotoxicity and resistance to immunosuppressive microenvironment in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ethan Q, Li, Xiu-ling, Wang, Chun-rong, Li, Tian-fang, Han, Shuang-yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706354/
https://www.ncbi.nlm.nih.gov/pubmed/23829929
http://dx.doi.org/10.1186/1756-8722-6-47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706354/
https://www.ncbi.nlm.nih.gov/pubmed/23829929
http://dx.doi.org/10.1186/1756-8722-6-47

Ejemplares similares